Role of chemotherapy for survival in patients with second primary non-small cell lung cancer

被引:2
作者
Wang, Zhile [1 ,2 ]
Wu, Yijun [1 ,2 ]
Wang, Li [1 ,2 ]
Gong, Liang [2 ]
Han, Chang [2 ]
Xie, Fucun [2 ]
Li, Shanqing [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Thorac Surg, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci, Eight Year MD Program, Peking Union Med Coll, Beijing, Peoples R China
关键词
Chemotherapy; initial primary lung cancer; prognostic study; second primary lung cancer; TUMORS; PROGNOSIS;
D O I
10.1111/1759-7714.13762
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The therapeutic effect of chemotherapy is still unclear for clinical usage among second primary non-small cell lung cancer (NSCLC) patients. The aim of this study was to verify the therapeutic effect of chemotherapy and identify the prognostic factors among patients who had received chemotherapy for second primary NSCLC. Methods A retrospective cohort was constructed based on the Surveillance, Epidemiology and End Results (SEER) database. Through least absolute shrinkage and selection operator regression, univariate Cox and multivariate Cox regression, we identified the prognostic factors among clinicopathological features. Propensity score matching analysis was used to verify the therapeutic effect of chemotherapy. Survival curves were plotted among the subgroups of the selected factors. We further selected clinicopathological features that would affect the prognosis among patients who had received chemotherapy through a similar process. Results A total of 769 patients were enrolled to verify the therapeutic value of chemotherapy for second primary lung cancer. Significant differences were observed between the chemotherapy and nonchemotherapy group for cancer-specific survival. 215 patients who had received chemotherapy were analyzed to identify the factors that might influence outcome on the therapeutic effect of chemotherapy. Age, tumor size, histology and treatment were selected as significant factors. Conclusions The therapeutic effect of chemotherapy for second primary NSCLC was found to be significant. Age, tumor size and histology were significant prognostic factors among patients who had received chemotherapy for second primary NSCLC. Key points Significant findings of the study A significant therapeutic effect of chemotherapy for second primary non-small cell lung cancer was proven through univariate Cox regression and propensity score matching analysis. Prognostic factors for second primary non-small cell lung cancer patients who had received chemotherapy. What this study adds Chemotherapy could be applied in clinical practice as an additional therapeutic method for second primary non-small cell lung cancer patients. We selected prognostic factors for patients who had received chemotherapy to identify patients who were appropriate for chemotherapy.
引用
收藏
页码:426 / 443
页数:18
相关论文
共 21 条
  • [1] Adamo M., 2018, SEER Program Coding and Staging Manual 2018
  • [2] The Role of Surgical Treatment in Second Primary Lung Cancer
    Bae, Mi Kyung
    Byun, Chun Sung
    Lee, Chang Young
    Lee, Jin Gu
    Park, In Kyu
    Kim, Dae Joon
    Chung, Kyung Young
    [J]. ANNALS OF THORACIC SURGERY, 2011, 92 (01) : 256 - 263
  • [3] Statistical primer: propensity score matching and its alternatives
    Benedetto, Umberto
    Head, Stuart J.
    Angelini, Gianni D.
    Blackstone, Eugene H.
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2018, 53 (06) : 1112 - 1117
  • [4] Analysis of Second Primary Lung Cancers in the SEER Database
    Bhaskarla, Amrit
    Tang, Paul C.
    Mashtare, Terry
    Nwogu, Chukwumere E.
    Demmy, Todd L.
    Adjei, Alex A.
    Reid, Mary E.
    Yendamuri, Sai
    [J]. JOURNAL OF SURGICAL RESEARCH, 2010, 162 (01) : 1 - 6
  • [5] Statistical Tools for Propensity Score Matching
    Duhamel, Alain
    Labreuche, Julien
    Gronnier, Caroline
    Mariette, Christophe
    [J]. ANNALS OF SURGERY, 2017, 265 (06) : E79 - E80
  • [6] Outcome and Prognostic Factors in Bronchial Carcinoids A Single-Center Experience
    Filosso, Pier Luigi
    Oliaro, Alberto
    Ruffini, Enrico
    Bora, Giulia
    Lyberis, Paraskevas
    Asioli, Sofia
    Delsedime, Luisa
    Sandri, Alberto
    Guerrera, Francesco
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (10) : 1282 - 1288
  • [7] Gray E, 2019, PLOS MED, V16, DOI [10.1371/journal.pmed.1003006, 10.1371/journal.pmed.1003006.r001, 10.1371/journal.pmed.1003006.r002, 10.1371/journal.pmed.1003006.r003, 10.1371/journal.pmed.1003006.r004]
  • [8] Gross Jefferson Luiz, 2019, J. bras. pneumol., V45, pe20180140, DOI 10.1590/1806-3713/e20180140
  • [9] A Meta-Analysis of Resected Metachronous Second Non-Small Cell Lung Cancer
    Hamaji, Masatsugu
    Ali, Syed Osman
    Burt, Bryan M.
    [J]. ANNALS OF THORACIC SURGERY, 2015, 99 (04) : 1470 - 1478
  • [10] Second lung cancers in patients after treatment for an initial lung cancer
    Johnson, BE
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18): : 1335 - 1345